Excited for the @ESMO #VirtualPlenary on "Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated" Starting now..Heather Wakelee Luis Paz-Ares Martin Reck Hem-Onc Fellows Network

The #ESMOVirtualPlenary presented by Dr. Luis Paz-Ares presents results from EORTC-1416-LCG / ETOP 8-15 / PEARLS / KEYNOTE-091: adjuvant pembrolizumab versus placebo for resected early stage #NSCLC. ESMO - Eur. Oncology 🧵

Poster session #AACR22 on osimertinib resistance in EGFR-mutant lung cancer from @Fdemiguelsdp Dr. Katerina Politi @RimmLaboratory Robert Homer Maria Toki Wesley Cai, PhD and colleagues. Stop by section 23. Smilow Cancer Hospital Yale School of Medicine @YalePathology bit.ly/3ulCjrw

Hot off the press in the Journal of Thoracic Disease! First of 4 articles on how to decide b/t various treatments when seeing a patient w/stage 1 #NSCLC in clinic. Great multidisciplinary collaboration! #lungcancer Yale Cancer Center Yale School of Medicine Smilow Cancer Hospital Yale New Haven Hosp jtd.amegroups.com/article/view/6…

Rural residents suffer higher cancer-related mortality than their urban counterparts. This has resulted in widening disparities in the last 20 years. Take a peek at our work at #ASCO22 with Arjun Gupta. Highlighted here by #ASCODailyNews ASCO fal.cn/3oXiu

Great discussion ASCO ‘22 by Sarah Goldberg on lung cancer brain mets

Out today in Blood Advances, we show stark disparities in access to end-of-life care for individuals with hematologic malignancies living in Rural America Our findings and thoughts on this important, nuanced & policy-relevant topic below. We can do better bit.ly/3xUbyfx

Survival benefit in ADAURA: adjuvant osimertinib for resected #EGFR NSCLC hits secondary endpoint of overall survival. For those not convinced by the profound DFS benefit (HR 0.23 in stage II/IIIA), we now have OS data. Patrick Forde @DrSteveMartin astrazeneca.com/media-centre/p…

Hot off the press Clinical Cancer Research Yale School of Medicine Yale Cancer Center Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations aacrjournals.org/clincancerres/…

So fortunate to share our The Lancet preprint. This is proof-of-concept showing that unanswered clinical questions in rare diseases can be accomplished by global collaboration across tens of centers! TOOK A VILLAGE to answer this and hopefully more similar efforts to come.

IMscin001 (NCT03735121) was a randomized phase III trial investigating anti-PDL1 MoAb Atezolizumab as a SC formulation 💉 in NSCLC 🫁 Results of this non-inferiority study are now available #openaccess in Annals of Oncology: annalsofoncology.org/article/S0923-… #lcsm

At #EHA2023 - Learn about the genomic evolution & resistance to a highly selective, non-covalent (reversible) BTK inhibitor in patients with CLL that were previously treated with a covalent BTK inhibitor (cBTKi). #leusm #lymsm See the details here: e.lilly/45ONFVC

Excited to share our recent work now published in JTO & JTO CRR: 👉Pts with #EGFR mt NSCLC with co-mut in TP53 and another suppressor gene have ⬆️aggressive dz and ⬇️outcomes on TKIs. 👉These findings may help to identify pts for Tx strategies beyond Osi. jto.org/article/S1556-…

“Approximately half of the patients who experience disease progression s/p definitive CCRT & IO per PACIFIC regimen have low-volume relapse or oligometastatic relapse & therefore are candidates for further potentially curative-intent ablative therapy.” IASLC OncoAlert #lcsm

Beyond the EGFR mutations in EGFR mutant lung cancer Paul Stockhammer

In NSCLC IO trials, the moderate link between ORR & PFS and OS necessitates thorough OS analyses, even if initial PFS results are not promising. This critical measure ensures potential survival benefits are not overlooked. Bernardo Haddock Lobo Goulart Harpreet Singh, MD FDA Oncology

Yes, Alina trial changes SOC in resected ALK+ NSCLC. Remarkable that result achieved without chemotherapy.

Enjoyed sharing our work on ERBB2 mutations in Lung Cancer with a Merit Award from Conquer Cancer, the ASCO Foundation! Thanks to Paul Stockhammer for spearheading this effort, Michael Grant Dr. Katerina Politi #SarahGoldberg for the immense mentorship and to Yale IM Traditional Residency Program for their support! #ASCO24

Thanks JTO & JTO CRR for the opportunity to comment on this important topic. Strong data support 🫁 screening in smokers but I don't think we are ready to expand criteria to low-risk patients without more data on their survival benefit. More thoughts here: authors.elsevier.com/a/1jYFE_ZOPrsh…